Compare STRIDES PHARMA SCIENCE with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs FULFORD INDIA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE FULFORD INDIA STRIDES PHARMA SCIENCE/
FULFORD INDIA
 
P/E (TTM) x 16.4 398.8 4.1% View Chart
P/BV x 1.0 6.2 16.2% View Chart
Dividend Yield % 0.5 0.1 571.7%  

Financials

 STRIDES PHARMA SCIENCE   FULFORD INDIA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
FULFORD INDIA
Mar-14
STRIDES PHARMA SCIENCE/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,147942 121.8%   
Low Rs642450 142.7%   
Sales per share (Unadj.) Rs317.2691.4 45.9%  
Earnings per share (Unadj.) Rs7.811.5 68.4%  
Cash flow per share (Unadj.) Rs25.115.4 163.1%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.3 77.8%  
Book value per share (Unadj.) Rs274.3380.0 72.2%  
Shares outstanding (eoy) m89.503.90 2,294.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.81.0 280.1%   
Avg P/E ratio x114.060.7 187.8%  
P/CF ratio (eoy) x35.745.3 78.8%  
Price / Book Value ratio x3.31.8 178.1%  
Dividend payout %25.517.4 146.1%   
Avg Mkt Cap Rs m80,0582,714 2,949.4%   
No. of employees `0002.50.4 564.6%   
Total wages/salary Rs m4,341505 859.5%   
Avg. sales/employee Rs Th11,325.86,073.0 186.5%   
Avg. wages/employee Rs Th1,731.41,137.4 152.2%   
Avg. net profit/employee Rs Th280.1100.7 278.2%   
INCOME DATA
Net Sales Rs m28,3942,696 1,053.0%  
Other income Rs m941125 750.1%   
Total revenues Rs m29,3342,822 1,039.6%   
Gross profit Rs m3,965-46 -8,546.1%  
Depreciation Rs m1,54015 10,134.2%   
Interest Rs m1,96210 20,656.8%   
Profit before tax Rs m1,40354 2,584.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m9710 1,013.5%   
Profit after tax Rs m70245 1,570.7%  
Gross profit margin %14.0-1.7 -811.6%  
Effective tax rate %6.917.7 39.2%   
Net profit margin %2.51.7 149.2%  
BALANCE SHEET DATA
Current assets Rs m24,8361,738 1,428.7%   
Current liabilities Rs m18,993545 3,486.9%   
Net working cap to sales %20.644.3 46.5%  
Current ratio x1.33.2 41.0%  
Inventory Days Days7148 146.4%  
Debtors Days Days1134 2,634.5%  
Net fixed assets Rs m34,28912 288,141.3%   
Share capital Rs m89539 2,294.9%   
"Free" reserves Rs m23,6511,443 1,639.0%   
Net worth Rs m24,5461,482 1,656.2%   
Long term debt Rs m15,5130-   
Total assets Rs m65,4372,077 3,151.0%  
Interest coverage x1.76.7 25.5%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.3 33.4%   
Return on assets %4.12.6 156.0%  
Return on equity %2.93.0 94.8%  
Return on capital %6.94.3 160.1%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m15,69717 91,262.2%   
Fx outflow Rs m735673 109.2%   
Net fx Rs m14,962-656 -2,280.9%   
CASH FLOW
From Operations Rs m1,87190 2,078.6%  
From Investments Rs m5,826105 5,569.7%  
From Financial Activity Rs m-10,157-14 72,034.8%  
Net Cashflow Rs m-2,615181 -1,448.7%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 37.8 3.8 994.7%  
FIIs % 8.6 0.1 8,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 21.2 122.2%  
Shareholders   56,241 4,783 1,175.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT  VENUS REMEDIES  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 3, 2020 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS